| Daré Bioscience (darebioscience.com)

Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key Catalysts | Daré Bioscience (darebioscience.com)

We are excited to announce that the FDA has cleared our investigational new drug (IND) application for DARE-VVA1, a novel intravaginal proprietary formulation of tamoxifen being developed as a non-hormonal treatment option for moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy (VVA) associated with menopause.

Daré Bioscience Placed #1 in the Small Company Category of the San Diego Business Journal’s “2023 Best Places to Work” (Subscription required)